An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes

CompletedOBSERVATIONAL
Enrollment

1,297

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Interventions
DRUG

pramlintide acetate

Subcutaneous injection prior to each major meal

Trial Locations (107)

Unknown

Research Site, Birmingham

Research Site, Montgomery

Research Site, Tucson

Research Site, Anaheim

Research Site, Encinitas

Research Site, Escondido

Research Site, Fresno

Research Site, Lafayette

Research Site, Moreno Valley

Research Site, Sacramento

Research Site, Salinas

Research Site, Santa Barbara

Research Site, Torrance

Research Site, Vacaville

Research Site, Arvada

Research Site, Aurora

Research Site, Norwalk

Research Site, Wilmington

Research Site, Hialeah

Research Site, Jacksonville

Research Site, Maitland

Research Site, Melbourne

Research Site, Miami

Research Site, Plantation

Research Site, Tallahassee

Research Site, Winter Haven

Research Site, Canton

Research Site, Columbus

Research Site, Roswell

Research Site, Valdosta

Research Site, ‘Aiea

Research Site, Caldwell

Research Site, Idaho Falls

Research Site, Pocatello

Research Site, Evergreen Park

Research Site, Wheaton

Research Site, Fort Wayne

Research Site, Franklin

Research Site, Indianapolis

Research Site, Des Moines

Research Site, Shawnee Mission

Research Site, Wichita

Research Site, Louisville

Research Site, Baton Rouge

Research Site, Lafayette

Research Site, Laplace

Research Site, Glen Burnie

Research Site, Towson

Research Site, Ann Arbor

Research Site, Bloomfield

Research Site, Detroit

Research Site, Grand Rapids

Research Site, Duluth

Research Site, Eagan

Research Site, Butte

Research Site, Las Vegas

Research Site, Reno

Research Site, Hamilton

Research Site, Jersey City

Research Site, Livingston

Research Site, Moorestown

Research Site, Neptune City

Research Site, North Plainfield

Research Site, Albany

Research Site, Binghamton

Research Site, Forest Hills

Research Site, Lawrence

Research Site, New York

Research Site, Riverhead

Research Site, Rochester

Research Site, Staten Island

Research Site, Utica

Research Site, Greensboro

Research Site, Morehead City

Research Site, Raleigh

Research Site, Cincinnati

Research Site, Columbus

Research Site, Mentor

Research Site, Toledo

Research Site, Portland

Research Site, Salem

Research Site, Bridgeville

Research Site, Carlisle

Research Site, Erie

Research Site, Sewickley

Research Site, Columbia

Research Site, Orangeburg

Research Site, Sumter

Research Site, Chattanooga

Research Site, Hendersonville

Research Site, Hixon

Research Site, Memphis

Research Site, Nashville

Research Site, Austin

Research Site, Beaumont

Research Site, Houston

Research Site, San Antonio

Research Site, Provo

Research Site, Salt Lake City

Research Site, McLean

Research Site, Norton

Research Site, Puyallup

Research Site, Seattle

Research Site, Spokane

Research Site, Tacoma

Research Site, Walla Walla

Research Site, Milwaukee

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT00229658 - An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes | Biotech Hunter | Biotech Hunter